SCHEMBL10243981

SCHEMBL10243981

CCN(CCNC(=O)OC)C(C)c1ccccc1[N+](=O)[O-]

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
POLB P06746 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYP1A2 P05177 2/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
PKM P14618 1/20 0.37
PRMT5 O14744 1/20 0.37
WDR77 Q9BQA1 1/20 0.37
MAPT P10636 2/20 0.36
NPC1 O15118 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 1/20 0.36
HPGD P15428 1/20 0.36
PTPN1 P18031 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243117 0.82 L3MBTL1 (0.41) ALDH1A1POLBTSHRKMT2ANPSR1
SCHEMBL10243634 0.82 TSHR (0.40) ALDH1A1POLBCYP2C19TSHRHPGD
SCHEMBL10243454 0.82 KDM4E (0.37) POLBMAPTLMNAGAAHPGD
SCHEMBL10243715 0.81 ALDH1A1 (0.43) ALDH1A1POLBCYP2C19CYP1A2TSHR
SCHEMBL10243522 0.81 MC4R (0.45) ALDH1A1POLBCYP2C19KMT2ALMNA
SCHEMBL10244008 0.81 OPRM1 (0.40) TSHRKMT2ASMN1; SMN2LMNA
SCHEMBL10243705 0.80 HCRTR1 (0.43) TSHRKMT2ASMN1; SMN2LMNAGAA
SCHEMBL10243592 0.79 EPHX2 (0.43) ALDH1A1KMT2ALMNAGAAMEN1
SCHEMBL10243802 0.79 MGLL (0.45) ALDH1A1POLBKMT2ASMN1; SMN2MAPT
SCHEMBL10244104 0.78 HPGD (0.40) ALDH1A1POLBKMT2ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 ALDH1A1 1939/4885POLB 3348/4885CYP2C19 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.